Related Experiment Video
Updated: Jun 10, 2026
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
Published on: November 20, 2011
Tumor-on-chip platforms for transport phenotyping: decoding CAF-driven barriers to drug delivery
Doriane Le Manach1, Vincent Senez2, Matthias Nees1,3
1Department of Biochemistry and Molecular Biology, Medical University of Lublin, W. Chodźki 1 Street, 20-093 Lublin, Poland. matthias.nees@umlub.edu.pl.
Abstract:
Physical barriers within solid tumors constitute a fundamental but often overlooked mechanism of therapeutic resistance, contributing to the poor success rate of cancer drug translation. Therapeutic molecules often fail to reach their intended targets due to mass-transport limitations imposed by the remodeled, spatially heterogeneous tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) drive dynamic remodeling of the extracellular matrix (ECM), generating local variations in stiffness, porosity, and intrinsic permeability that, together, shape evolving transport phenotypes that govern drug accessibility. We focus on mechanical pathways of stromal mechanotransduction, tracing the sequence from CAF activation through ECM remodeling, to barrier formation, and show how these processes collectively govern therapeutic outcomes. We also evaluate advanced microfluidic and tumor-on-chip (ToC) platforms that reproduce stromal heterogeneity under controlled conditions, mimicking tissue architecture, transport behavior, and therapeutic response. By enabling patient-specific profiling of CAF-driven transport phenotypes, these systems demonstrate that transport barriers are not fixed obstacles but dynamically modifiable therapeutic targets. "Transport phenotyping" could complement genomic profiling in clinical oncology by integrating heterogeneity, biophysics, and precision medicine, potentially transforming personalized treatment strategies for patients whose tumors remain refractory to current therapies.
Insights
Physical barriers in tumors, driven by cancer-associated fibroblasts (CAFs), limit drug delivery and treatment success. Understanding these transport phenotypes offers new therapeutic targets for precision medicine.
Area of Science:
- Oncology
- Biophysics
- Biomaterials Science
Background:
- Solid tumors possess physical barriers hindering drug delivery, a key factor in therapeutic resistance.
- The tumor microenvironment (TME), remodeled by cancer-associated fibroblasts (CAFs), exhibits spatial heterogeneity impacting drug transport.
- Understanding extracellular matrix (ECM) remodeling and stromal mechanotransduction is crucial for overcoming drug delivery challenges.
Purpose of the Study:
- To investigate how CAF-driven ECM remodeling creates transport barriers within solid tumors.
- To explore the role of stromal mechanotransduction in governing therapeutic outcomes.
- To evaluate advanced microfluidic and tumor-on-chip (ToC) platforms for profiling CAF-driven transport phenotypes.
Main Methods:
- Analysis of CAF activation and subsequent ECM remodeling.
- Investigation of mechanical pathways of stromal mechanotransduction.
- Utilizing microfluidic and tumor-on-chip (ToC) platforms to mimic TME heterogeneity and assess drug transport.
- Development of "transport phenotyping" to characterize barrier properties.
Main Results:
- CAF-driven ECM remodeling leads to heterogeneous transport phenotypes that limit drug accessibility.
- These physical barriers dynamically influence therapeutic molecule delivery and efficacy.
- Advanced ToC platforms successfully replicate TME architecture, transport behavior, and therapeutic response.
- Transport barriers were identified as dynamically modifiable targets, not fixed obstacles.
Conclusions:
- Transport barriers are critical, modifiable targets in cancer therapy.
- "Transport phenotyping" offers a complementary approach to genomic profiling for personalized oncology.
- Integrating biophysics and precision medicine through transport phenotyping can improve treatment strategies for refractory tumors.
